(Source: illumina.com) November 2024: Ascendis Pharma licensed its TransCon technology to Novo Nordisk for metabolic and cardiovascular drug development, including a monthly GLP-1 agonist for obesity and diabetes
These products offered medical-grade quality with physician oversight
Now weve entered a new era of weight loss with a groundbreaking class of medications known as GLP-1 inhibitors
Back Pain and GLP-1 Assisted Weight Loss: A New Path to Relief PUBLISHED ON: December 23, 2025 CATEGORIES: RECENT POSTS: Back pain is one of the most common health complaints worldwide, affecting an estimated 619 million people globally
Sarnoff strongly cautions that whether youre wishing for lighter or darker skin tones, None of this is worth the risks! Krista Bennett DeMaio is a writer, editor and content strategist who covers beauty, health and wellness
Still, patients can manage it by staying well-hydrated, avoiding large meals, and using medications like the ondansetron mentioned above